SoundBite Crossing System - Peripheral (14P)
Device Facts
| Record ID | K210839 |
|---|---|
| Device Name | SoundBite Crossing System - Peripheral (14P) |
| Applicant | Soundbite Medical Solutions, Inc. |
| Product Code | PDU · Cardiovascular |
| Decision Date | Apr 20, 2021 |
| Decision | SESE |
| Submission Type | Special |
| Regulation | 21 CFR 870.1250 |
| Device Class | Class 2 |
| Attributes | Therapeutic |
Indications for Use
The SoundBite® Crossing System - Peripheral (14P) is indicated to facilitate the intraluminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions. The SoundBite® Crossing System - Peripheral (14P) is not intended for use in the carotid arteries.
Device Story
The SoundBite Crossing System - Peripheral (14P) is a recanalization tool used by physicians in clinical settings to cross peripheral artery chronic total occlusions (CTOs). The system consists of a reusable mobile console and a single-use sterile titanium alloy active wire (0.014" diameter). The console generates controlled mechanical pulses (shock waves) transmitted along the wire, causing the distal tip to accelerate axially in a reciprocating motion, functioning as a micro-jackhammer. This mechanical action facilitates the advancement of the wire through occlusions, allowing for the subsequent placement of conventional guidewires or treatment devices. The device benefits patients by enabling successful crossing of complex arterial blockages. Physicians operate the system via a footswitch, monitoring the procedure to guide the wire through the vasculature.
Clinical Evidence
Bench testing only. No clinical data. Verification and validation included visual/dimensional inspection, simulated use, coating integrity, tip pull, flexibility, fracture resistance, torque/tensile strength, corrosion resistance, distal temperature, lubricity, and particulate testing. Console testing included output stability, life-cycle, and electrical/software verification per ANSI AAMI ES60601-1 and IEC 60601-1-2. Biocompatibility testing performed per GLP. Summative usability evaluation confirmed safe use without serious errors.
Technological Characteristics
System comprises a mobile AC-powered console and a 300 cm titanium alloy active wire (0.014" diameter). Wire features PTFE coating (excluding distal tip) and a radiopaque marker. Principle of operation is mechanical pulse-driven axial reciprocation. Sterilization via Ethylene Oxide. Software verified per IEC 62304. Electrical safety per ANSI AAMI ES60601-1 and electromagnetic compatibility per IEC 60601-1-2.
Indications for Use
Indicated for patients with peripheral artery chronic total occlusions to facilitate intraluminal placement of guidewires or treatment devices. Not for use in carotid arteries.
Regulatory Classification
Identification
A percutaneous catheter is a device that is introduced into a vein or artery through the skin using a dilator and a sheath (introducer) or guide wire.
Predicate Devices
- SoundBite® Crossing System – Peripheral (K192211)
Submission Summary (Full Text)
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo is in blue and includes the letters "FDA" in a square and the words "U.S. Food & Drug Administration".
April 20, 2021
Soundbite Medical Solutions, Inc. Dominique Abecassis Director, Compliance 2300 Boulevard Alfred-Nobel Montreal, Quebec H4S 2A4 Canada
Re: K210839
Trade/Device Name: SoundBite Crossing System - Peripheral (14P) Regulation Number: 21 CFR 870.1250 Regulation Name: Percutaneous catheter Regulatory Class: Class II Product Code: PDU Dated: March 18, 2021 Received: March 22, 2021
#### Dear Dominique Abecassis:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
{1}------------------------------------------------
801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Gregory O'Connell Assistant Director DHT2C: Division of Coronary and Peripheral Intervention Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
## Indications for Use
510(k) Number (if known) K210839
Device Name SoundBite® Crossing System - Peripheral (14P)
Indications for Use (Describe)
SoundBite® Crossing System - Peripheral (14P) is indicated to facilitate the intraluminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions.
SoundBite® Crossing System - Peripheral (14P) is not intended for use in the carotid arteries.
Type of Use (Select one or both, as applicable)
| <div> <span style="font-size:100%;">☒</span> Prescription Use (Part 21 CFR 801 Subpart D) </div> |
|--------------------------------------------------------------------------------------------------------------|
| <div> <span>☐</span> Over-The-Counter Use (21 CFR 801 Subpart C) </div> |
#### CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
#### K210839
Page 1 of 4
## 510(K) Summary
As required by 21 CFR 807.92
| Date Prepared: | 15 March 2021 |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------|
| Submitted by: | Soundbite Medical Solutions, Inc. |
| | 2300 Boulevard Alfred-Nobel,<br>Montreal, Quebec, Canada<br>H4S 2A4 |
| Contact: | Dominique Abecassis<br>Director, Compliance<br>Tel: (514) 956-2525 x 3352<br>Fax: (514) 956-2529<br>E-mail: dominique.abecassis@soundbitemedical.com |
| Trade/Device Name: | SoundBite® Crossing System – Peripheral (14P) |
| Common Name: | System for Crossing Total Occlusions |
| Regulation: | 21 CFR 870.1250, Percutaneous Catheter |
| Device Class: | Class II |
| Product Code: | PDU (Catheter for Crossing Total Occlusions) |
| Predicate Device: | SoundBite® Crossing System – Peripheral by Soundbite Medical<br>Solutions Inc. (K192211) |
### Device Description:
The SoundBite® Crossing System - Peripheral (14P) is a recanalization tool, designed to help physician's placement of conventional guidewires or treatment devices in the intraluminal space beyond chronic total occlusions in the peripheral vasculature. The SoundBite® Crossing System - Peripheral (14P) consists of the reusable mobile SoundBite® Console, a single-use sterile SoundBite® Active Wire 14P, and their respective accessories.
The SoundBite® Console generates controlled mechanical pulses (i.e., shock waves) which are transmitted to the SoundBite® Active Wire 14P and cause the distal tip of the wire to accelerate axially in a reciprocating motion, acting like a micro-jackhammer.
The SoundBite® Active Wire 14P is similar in construction to the 0.018" CTO crossing wire provided with the predicate device, with a friction reducing PTFE coating (except for the distal tip), a radiopaque marker near the tip, and enhanced flexibility at the distal end. It has an outer
{4}------------------------------------------------
diameter of 0.36 mm (0.014") and it is 300 cm long, with a working length of 145 cm. At the proximal end of the SoundBite® Active Wire 14P, a section reducer allows the wire to be connected to the SoundBite® Console. The single-use SoundBite® Active Wire 14P is supplied sterile with a shelf life of 24 months.
# Intended Use / Indications for Use:
The SoundBite® Crossing System - Peripheral (14P) is indicated to facilitate the intraluminal placement of conventional guidewires or treatment devices beyond peripheral artery chronic total occlusions.
The SoundBite® Crossing System - Peripheral (14P) is not intended for use in the carotid arteries.
## Substantial Equivalence Comparison:
The SoundBite® Crossing System - Peripheral (14P) is substantially equivalent to the predicate device, the SoundBite® Crossing System - Peripheral (K192211), in intended use and indications for use, fundamental technologies, principles of operation, and labeling. Non-clinical bench testing data, and performance data from animal studies have been submitted to demonstrate that the differences in device characteristics do not raise questions related to safety or performance. A side-by-side comparison of key device characteristics is presented in the following table:
| Device<br>Characteristic | Predicate Device 510(k) K192211<br>SoundBite® Crossing System – Peripheral | SoundBite® Crossing System –<br>Peripheral (14P) |
|-------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| System<br>Components | ■ AC-powered, mobile SoundBite®<br>Console generator and footswitch.<br>■ Single-use SoundBite® Active Wire 18 | ■ AC-powered, mobile SoundBite®<br>Console generator and footswitch.<br>■ Single-use SoundBite® Active Wire 14P |
| Mechanism of<br>Action | Mechanical pulses sent along the length of<br>the Titanium alloy SoundBite® Active Wire<br>cause the distal tip to accelerate axially in a<br>reciprocating (back-and-forth) motion,<br>acting like a micro-jackhammer. | Mechanical pulses sent along the length of<br>the Titanium alloy SoundBite® Active Wire<br>cause the distal tip to accelerate axially in a<br>reciprocating (back-and-forth) motion, acting<br>like a micro-jackhammer. |
| Console Setting:<br>Pulse Repetition<br>Rate (PRR) | 10 Hz | 20 Hz |
| Wire Connection | Titanium alloy section reducer for<br>connection to the SoundBite® Console | Titanium alloy section reducer for<br>connection to the SoundBite® Console |
| Maximum<br>Active Wire<br>Diameter<br>over Usable<br>Length | 0.46 mm (0.018") | 0.36 mm (0.014") |
| Working<br>Length | 150 cm | 145 cm |
| Radiopaque Marker | 10 mm radiopaque coil starting at 1.5 mm<br>from the distal tip | 10 mm radiopaque coil starting at 0.75 mm<br>from the distal tip |
{5}------------------------------------------------
| Device<br>Characteristic | Predicate Device 510(k) K192211<br>SoundBite® Crossing System – Peripheral | SoundBite® Crossing System –<br>Peripheral (14P) |
|--------------------------|----------------------------------------------------------------------------|-------------------------------------------------------------------------|
| Wire Shaft Diameter | 0.46 mm (0.018") | 0.36 mm (0.014") |
| Wire Tip Diameter | 0.29 mm (0.0115") | 0.27 mm (0.0105") |
| Wire Material | Titanium alloy | Titanium alloy |
| Wire Coating | PTFE coating on main body of the wire only;<br>no coating on distal end | PTFE coating on main body of the wire only;<br>no coating on distal end |
| Wire Sold Sterile | Yes | Yes |
| Sterilization Method | Ethylene Oxide | Ethylene Oxide |
| Shelf Life | 24 months | 24 months |
## Summary of Non-Clinical Testing:
Design verification and validation testing was conducted following systematic risk assessment in accordance with the FDA-recognized consensus standard ISO 14971 and FDA guidance.
Substantial equivalence of the device, both at the system and component levels (i.e., sterility assurance to the point of care, packaging integrity and shelf-life, biocompatibility, electrical/mechanical safety, and electromagnetic compatibility) has been verified and/or validated in accordance with current FDA-recognized consensus standards and regulatory requirements. The medical device software system has been designed, and verified in compliance with the FDA-recognized consensus standard IEC 62304.
SoundBite® Crossing System - Peripheral (14P) was assessed in the following areas:
- . Visual and dimensional inspection
- 트 Simulated use
- Coating integrity l
- Tip pull l
- l Flexibility resistance
- Fracture resistance l
- l Torque strength
- Tensile strength 트
- Corrosion resistance I
- l Torqueability
- Distal temperature i
- Tip flexibility .
- Catheter qualification l
- Lubricity assessment 트
- Particulate testing I
{6}------------------------------------------------
- 트 Shelf-life testing
SoundBite® Console was assessed in the following areas:
- 트 Console Output Stability
- Life-Cycle Testing 트
- Console and Shipping Container Labels Verification
- 트 Electronics and Software Verification
- 트 ANSI AAMI ES60601-1:2005/(R) 2012 and A1:2012
- IEC 60601-1-2 Edition 4.0 2014-02
Biocompatibility: A full panel of biocompatibility tests was successfully performed in accordance with product classification, under GLP, demonstrating that all utilized materials and methods of construction/processing passed biocompatibility requirements.
Usability: Representative users were included in a summative evaluation. The study confirms that the SoundBite® Crossing System - Peripheral (14P) can be used without serious use errors or problems, for the intended uses under the expected use conditions.
The results from bench testing indicate that the performance characteristics of the SoundBite® Crossing System - Peripheral (14P) are substantially equivalent to the predicate device and do not raise new questions of safety or performance.
### Conclusion:
The data submitted with this Special 510(k) premarket notification demonstrate that the SoundBite® Crossing System - Peripheral (14P) is substantially equivalent to the predicate device.
